Discover opportunities months before the RFP drops
Learn more →Retrieving contract details... Hang tight!
See what competitors charge and their contract structure
Spot renewal opportunities 6-12 months before expiration
Analyze buyer's purchasing history and vendor preferences
Track expiration dates across all your target accounts
Reach decision-makers before renewal with competitive intel
Our customers win 3x more contract renewals and replacements
Premium
Clean & enrich your CRM automatically
Premium
Get complete source documentation & analysis
This contract includes 1 purchase order from Jul 1, 2024 to Jul 1, 2024
| Buyer | Vendor | Issued Date | Quantity |
|---|---|---|---|
| National Institutes of Health NIDA | PPD Development, L.P. | Jul 1, 2024 | 1 |
Full Purchase Intelligence Available
Get complete pricing, descriptions, and financial details for all 1 purchase orders
Unlock Full Details →See what competitors charge and their contract structure
Spot renewal opportunities 6-12 months before expiration
Analyze buyer's purchasing history and vendor preferences
Track expiration dates across all your target accounts
Reach decision-makers before renewal with competitive intel
Our customers win 3x more contract renewals and replacements
No public files available for this contract.
Contract documentation may be available through official government sources or agency portals. Starbridge can help you track down and retrieve these files.
PHASE I RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY, AND PHARMACOKINETICS
Effective Date
Jul 15, 2024
Expires
Effective: Jul 15, 2024
PHASE I RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY, AND PHARMACOKINETICS
ActivePHASE I SINGLE ASCENDING DOSE STUDY. TO7. NIDA PHARMACOKINETIC ANALYSIS RESOURCE CENTER. 09/10/2024 - 03/09/2026. NIDA REF. NO. N01DA-19-8947.
Effective Date
Sep 9, 2024
Expires
PHASE I SINGLE ASCENDING DOSE STUDY. TO7. NIDA PHARMACOKINETIC ANALYSIS RESOURCE CENTER. 09/10/2024 - 03/09/2026. NIDA REF. NO. N01DA-19-8947.
ActiveA PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE ANTIVIRAL ACTIVITY, SAFETY, AND PHARMACOKINETICS OF NOVARTIS EYU688 AGAINST DENGUE VIRUS 2 INFECTION IN A CONTROLLED HUMAN INFECTION MODEL IN HEALTHY ADULT PARTICIPANTS
Effective Date
Aug 23, 2023
Expires
A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE ANTIVIRAL ACTIVITY, SAFETY, AND PHARMACOKINETICS OF NOVARTIS EYU688 AGAINST DENGUE VIRUS 2 INFECTION IN A CONTROLLED HUMAN INFECTION MODEL IN HEALTHY ADULT PARTICIPANTS
ActivePHARMACOKINETIC ANALYSIS RESOURCE CENTER. PHASE I SINGLE ASCENDING DOSE STUDY. MAY 15, 2025 - NOVEMBER 14, 2026. N01DA-25-8947. TASK ORDER 75N95025F00001 (TO1).
Effective Date
May 13, 2025
Expires
PHARMACOKINETIC ANALYSIS RESOURCE CENTER. PHASE I SINGLE ASCENDING DOSE STUDY. MAY 15, 2025 - NOVEMBER 14, 2026. N01DA-25-8947. TASK ORDER 75N95025F00001 (TO1).
ActiveSee who's winning contracts, track spending trends, and identify your best opportunities before your competition.
Schedule Your Demo →Premium
Clean & enrich your CRM automatically
Premium
Get complete source documentation & analysis